TNDM 10-Q report for 2026-03-31
Tandem Diabetes Care filed its Form 10‑Q for the quarter ended March 31, 2026. The filing includes condensed consolidated financial statements and interim results showing Q1 sales of $247.2 million, a net loss of $20.4 million, cash and cash equivalents of $179.3 million, and proceeds from convertible senior notes due 2032. This filing confirms the company’s reported interim financial position and capital-structure activity.
Linked assets
TNDM — Tandem Diabetes Care, Inc. (Nasdaq: TNDM). The 10‑Q discloses quarter-end financials, balance sheet, cash flow, and capital‑markets activity (notably issuance of convertible senior notes).
Tandem Diabetes Care, Inc. (TNDM) filed its Form 10‑Q for the quarter ended March 31, 2026. Key reported figures in the unaudited condensed consolidated financial statements include: sales of $247.2 million (Q1 2026), gross profit $136.8 million, operating loss $17.4 million, net loss $20.4 million, cash and cash equivalents $179.3 million, short-term investments $390.9 million, total assets $1,153.4 million, total liabilities $1,021.0 million (including $601.8 million long-term, net convertible senior notes), and 68,529,089 shares outstanding as of May 4, 2026.
The filing provides the company’s unaudited interim financial statements and certain balance sheet and cash flow details, confirming material items: Q1 revenue and net loss, a large increase in cash/short-term investments driven by financing activity, and the issuance of convertible senior notes due 2032. The document is primary financial disclosure and should be used to validate company-reported interim performance and capital-structure changes. It does not, however, include forward guidance or additional management commentary beyond the standard MD&A table of contents in the excerpt; investors should read the full 10‑Q for MD&A, risk factors, and note disclosures before forming a high-confidence directional trade.
Source proof
Source proof: Strong source proof | 1 directional asset | 1 supporting author | headline-like title review
Primary source: Tandem Diabetes Care, Inc. Form 10‑Q for the quarterly period ended March 31, 2026 (filed with the SEC). The filing contains unaudited condensed consolidated balance sheets, statements of operations, equity and cash flows, notes to the financial statements, and the Itemized table of contents for MD&A, risk factors and exhibits.
This excerpt is only the cover page/header of Sleep Number’s Form 10‑Q for the quarter ended April 4, 2026. It contains filing metadata (issuer, ticker, exchange, address) but no financial statements, MD&A, guidance, risks, or operational commentary. As a result, it is not directly actionable for trading beyond confirming the filing exists.
The provided excerpt is only the cover/filing header of SoundHound AI, Inc.’s 10‑Q for the quarter ended 2026‑03‑31. It contains listing/security identifiers (SOUN, SOUNW) but no financial statements, MD&A, guidance, risk updates, liquidity details, or material events. As a result, there is insufficient information to form high-confidence, actionable bullish/bearish theses beyond generic “company filed its 10‑Q” metadata.
The provided excerpt is only the boilerplate cover/filing-status section of Teucrium Commodity Trust’s Form 10‑Q for period ended 2026‑03‑31, with no portfolio holdings, performance, risk, or material updates included. As-is, it contains no actionable investment information beyond confirming the existence of the filing and the issuer/ticker identity (WEAT).
This excerpt is only the cover page of Archer Aviation’s Form 10‑Q for the quarter ended 2026‑03‑31 (issuer identity, exchange listing, and securities outstanding). It contains no operating/financial results, guidance, liquidity details, backlog, or risk-factor updates—so it is minimally actionable for trading beyond basic security identifiers and a generic dilution/optionality consideration from warrants.
This excerpt is essentially the cover page of CleanSpark, Inc.’s Form 10-Q for the quarter ended March 31, 2026. It contains identifiers (CIK/file no.), listing venue, and security descriptions (common stock and redeemable warrants with specific exercise terms), but no operating/financial results, guidance, risks, or MD&A detail. Actionability is therefore limited to capital-structure/dilution considerations around the listed warrant.
This excerpt of AST SpaceMobile’s 10‑Q is largely SEC cover-page/boilerplate (registrant info, exchange listing, filing compliance) and contains no financial results, guidance, liquidity, risk-factor updates, or operating metrics. As provided, it does not create a clear tradable catalyst beyond confirming continued reporting/listing status.
This excerpt only includes the cover page of Super Micro Computer, Inc.’s Form 10‑Q for the quarter ended March 31, 2026. It confirms the filing, issuer identity, listing (Nasdaq), and ticker (SMCI), but contains no financial results, guidance, risks, or MD&A content to support a directional investment view.
The provided text is only the cover/header portion of AbCellera Biologics Inc.’s Form 10‑Q for the quarter ended March 31, 2026 (identifying info, exchange listing, filing status). It contains no financial statements, guidance, risk updates, material events, MD&A, cash runway, pipeline/program updates, or disclosures that would support a differentiated trading view.
Supporting authors
Filed by Tandem Diabetes Care, Inc.; consolidated financial statements prepared in accordance with U.S. GAAP. No external analyst commentary is included in the filing excerpt.
Unlock full thesis monitoring
Review the full Form 10‑Q to inspect Management’s Discussion & Analysis, risk-factor updates, notes to the financial statements, convertible note terms and complete disclosures before making investment decisions.